Monte Rosa Therapeutics (GLUE) Change in Account Payables (2020 - 2026)

Monte Rosa Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 140.25% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 244.42% increase from a year earlier, with the FY2025 full-year figure at -$13.7 million, down 319.26% from the prior year.
• Change in Account Payables improved to $4.4 million in Q1 2026 per GLUE's latest filing, from -$10.6 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $13.3 million in Q4 2024 and bottomed at -$10.9 million in Q1 2025.
• The 5-year median for Change in Account Payables is $155000.0 (2022), against an average of $113823.5.
• Across the five-year window, Change in Account Payables soared 3621.29% in 2023 and tumbled 1756.86% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at $155000.0 in 2022, then surged by 3621.29% to $5.8 million in 2023, then surged by 130.72% to $13.3 million in 2024, then sank by 179.74% to -$10.6 million in 2025, then jumped by 141.25% to $4.4 million in 2026.
• Per Business Quant, the three latest GLUE Change in Account Payables figures stand at $4.4 million (Q1 2026), -$10.6 million (Q4 2025), and $8.9 million (Q3 2025).